



Attorney Docket No.: 5835.200-US

[Handwritten mark]

PATENT

Sector 4
(3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al

Serial No.: 09/710,339

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: To Be Assigned

For: Fungamyl-like Alpha-Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts (in duplicate)
2. Copy of Notice to File Missing Parts
4. Executed Combined Declaration and Power of Attorney


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on March 29, 2001.

Kelley O'Patry
(name of person mailing paper)

[Signature]
(signature of person mailing paper)




UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/710,339	11/09/2000	Henrik Bisgard-Frantzen	5835.200-US

Jason I Garbell Esq
 Novo Nordisk of North America Inc
 405 Lexington Avenue
 Suite 6400
 New York, NY 10174-6401

FORMALITIES LETTER



OC00000005717804

Date Mailed: 01/30/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

04/04/2001 FFANDEIA 00000025 501701 09710339 FILED UNDER 37 CFR 1.53(b)
 01 FC:105 130.00 CH Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT

3

Attorney Docket No.: 5835.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al

Serial No.: 09/710,339

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: To Be Assigned

For: Fungamyl-like Alpha-Amylase Variants

RESPONSE TO NOTICE TO FILE MISSING PARTS

Commissioner for Patents
Washington, DC 20231


Sir:

In response to the Notice to File Missing Parts dated January 30, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Please charge the required fee, estimated to be \$130.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. Please credit any overpayment to Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 29, 2001


Jason I. Garben, Reg. No., 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123